Third-year funds will be based on GenVec’s multiple adenovirus vectors and production cell-line technologies.
NIAID awarded GenVec $3.8 million in continued support on the development of new HIV vaccine candidates. This second option period under a previously announced, five-year CRADA with GenVec is valued at up to $52 million.
The renewal will help fund the development of new HIV vaccine candidates, which are based on multiple serotypes of adenovirus. GenVec’s adenovector technology platform now includes six distinct serotypes that can be used singly or in combination, according to Rick King, Ph.D., GenVec’s svp of research and development.
Under a separate contract, GenVec has produced adenovector-based HIV vaccines that have been tested in approximately 1,400 subjects in sixteen NIAID-sponsored Phase I and Phase II clinical trials.
